Skip to main content
. 2021 Jun 11;35(2):463–472. doi: 10.1007/s40620-021-01070-6

Fig. 1.

Fig. 1

Flow-chart of included patients. *Patients were considered as having hyperkalemia if they presented a serum potassium level ≥ 5.5 mmol/l. **Patients were considered as adherent to therapy if they had a proportion of days covered (PDC) > 80%. CKD chronic kidney disease, HK hyperkalemia, RAASi renin–angiotensin–aldosterone-system inhibitor